The investigation focuses on the conduct of Immunovant’s officers and directors, specifically questioning whether their actions prioritized personal interests over those of the company’s investors. Justin Kuehn, the lead attorney on the case, is currently soliciting feedback from long-term stockholders to determine the scope of the potential litigation.

Those interested in participating are encouraged to contact the firm directly to discuss their standing. Kuehn Law operates on a contingency model, meaning the legal process requires no upfront costs or financial obligation from the investors involved. Given the potential for time-sensitive filings, the firm is pushing for immediate contact to ensure that all legal rights are preserved throughout the investigative process.